Noveris Health Sciences Announces Private Placement Offering

Vancouver, British Columbia — March 12, 2026 — Leads & Copy — Noveris Health Sciences Inc. (CSE:NVRS) (FSE: 0NF0) (OTC: MYCOF) plans to complete a non-brokered private placement offering under the “listed issuer financing exemption”.

The LIFE Offering will involve a minimum of 6,250,000 units and a maximum of 10,416,666 units at $0.24 per unit, targeting gross proceeds between $1,500,000 and $2,500,000.

Each unit includes one common share of the company and one common share purchase warrant. Each warrant allows the holder to acquire an additional share at $0.30 for 24 months, starting from the closing date.

Noveris Health Sciences may pay cash finder’s fees up to 5% of the gross proceeds from investors introduced by finders.

The units will be offered in all Canadian provinces except Québec, subject to regulatory requirements. Securities issued to Canadian residents will not be subject to a hold period, with the exception of insiders and certain consultants, who will be subject to a four-month hold period.

An offering document is available on www.sedarplus.ca and the company’s website. Prospective investors are advised to read this document before making any investment decisions.

The LIFE Offering is expected to close around April 24, 2026, subject to customary conditions and CSE approval.

Noveris Health Sciences Inc. is a biotechnology company focused on developing medications and therapies for mental health disorders such as nicotine addiction and PTSD.

The company blends technology with infrastructure for drug discovery and development, aiming to develop breakthrough treatments and psychedelic medicines.

Source: Noveris Health Sciences Inc.